Education
About Us
Working with TipRanks
Follow Us
Y-Mabs Therapeutics (YMAB)
NASDAQ:YMAB
YMAB Analyst Ratings
Moderate Buy
6 Buy
0 Hold
2 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
YMAB Stock 12 Month Forecast
Average Price Target
$13.86
▲(188.75%Upside)
| Highest Price Target$26.00 | Average Price Target$13.86 | Lowest Price Target$3.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
JonesTrading
$18
Buy
275.00%
Upside
Reiterated
06/25/25
H.C. Wainwright
$11
Buy
129.17%
Upside
Reiterated
06/03/25
Truist Financial
―
Buy
―
Reiterated
05/29/25
Oppenheimer
$20→$15
Buy
212.50%
Upside
Reiterated
05/29/25
Clear Street
$17
Buy
254.17%
Upside
Reiterated
05/28/25
Morgan Stanley
$7
Sell
45.83%
Upside
Reiterated
05/28/25
Bank of America Securities
$3
Sell
-37.50%
Downside
Reiterated
05/28/25
Canaccord Genuity
$26
Buy
441.67%
Upside
Reiterated
05/28/25
Brookline Capital Markets
$17→$16
Buy
233.33%
Upside
Reiterated
03/04/25
Cantor Fitzgerald
$20→$19
Buy
295.83%
Upside
Reiterated
03/04/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
JonesTrading
$18
Buy
275.00%
Upside
Reiterated
06/25/25
H.C. Wainwright
$11
Buy
129.17%
Upside
Reiterated
06/03/25
Truist Financial
―
Buy
―
Reiterated
05/29/25
Oppenheimer
$20→$15
Buy
212.50%
Upside
Reiterated
05/29/25
Clear Street
$17
Buy
254.17%
Upside
Reiterated
05/28/25
Morgan Stanley
$7
Sell
45.83%
Upside
Reiterated
05/28/25
Bank of America Securities
$3
Sell
-37.50%
Downside
Reiterated
05/28/25
Canaccord Genuity
$26
Buy
441.67%
Upside
Reiterated
05/28/25
Brookline Capital Markets
$17→$16
Buy
233.33%
Upside
Reiterated
03/04/25
Cantor Fitzgerald
$20→$19
Buy
295.83%
Upside
Reiterated
03/04/25
Best Analysts Covering Y-Mabs Therapeutics
1 Month
xxx
Success Rate
6/9 ratings generated profit
Average Return
+5.26%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +5.26% per trade.
3 Months
xxx
Success Rate
5/9 ratings generated profit
Average Return
+12.11%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 55.56% of your transactions generating a profit, with an average return of +12.11% per trade.
1 Year
Success Rate
10/14 ratings generated profit
Average Return
+50.65%
reiterated a buy rating last month
Copying William Maughan's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +50.65% per trade.
2 Years
xxx
Success Rate
6/9 ratings generated profit
Average Return
+23.13%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +23.13% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
YMAB Analyst Recommendation Trends
Rating
Feb 25
Mar 25
Apr 25
May 25
Jun 25
Strong Buy
7
13
10
20
13
Buy
2
2
1
1
1
Hold
3
5
3
2
0
Sell
1
2
3
7
6
Strong Sell
0
0
0
0
0
total
13
22
17
30
20
Each month's total comprises the sum of three months' worth of ratings.
YMAB Financial Forecast
YMAB Stock Forecast FAQ
What is YMAB’s average 12-month price target, according to analysts?
Based on analyst ratings, Y-Mabs Therapeutics’s 12-month average price target is 13.86.
What is YMAB’s upside potential, based on the analysts’ average price target?
Y-Mabs Therapeutics has 188.75% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is YMAB a Buy, Sell or Hold?
Y-Mabs Therapeutics has a consensus rating of Moderate Buy which is based on 6 buy ratings, 0 hold ratings and 2 sell ratings.
What is Y-Mabs Therapeutics’s price target?
The average price target for Y-Mabs Therapeutics is 13.86. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $26.00 ,the lowest forecast is $3.00. The average price target represents 188.75% Increase from the current price of $4.8.
The highest analyst price target is $26.00 ,the lowest forecast is $3.00. The average price target represents 188.75% Increase from the current price of $4.8.
What do analysts say about Y-Mabs Therapeutics?
Y-Mabs Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 8 Wall Streets Analysts.
How can I buy shares of YMAB?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.